371 related articles for article (PubMed ID: 23082778)
21. Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis.
Bouchal P; Roumeliotis T; Hrstka R; Nenutil R; Vojtesek B; Garbis SD
J Proteome Res; 2009 Jan; 8(1):362-73. PubMed ID: 19053527
[TBL] [Abstract][Full Text] [Related]
22. The utility of isotope-coded protein labeling for prioritization of proteins found in ovarian cancer patient urine.
Rainczuk A; Condina M; Pelzing M; Dolman S; Rao J; Fairweather N; Jobling T; Stephens AN
J Proteome Res; 2013 Sep; 12(9):4074-88. PubMed ID: 23952987
[TBL] [Abstract][Full Text] [Related]
23. Urinary exosomes and diabetic nephropathy: a proteomic approach.
Raimondo F; Corbetta S; Morosi L; Chinello C; Gianazza E; Castoldi G; Di Gioia C; Bombardi C; Stella A; Battaglia C; Bianchi C; Magni F; Pitto M
Mol Biosyst; 2013 Jun; 9(6):1139-46. PubMed ID: 23344851
[TBL] [Abstract][Full Text] [Related]
24. Identification and confirmation of differentially expressed fucosylated glycoproteins in the serum of ovarian cancer patients using a lectin array and LC-MS/MS.
Wu J; Xie X; Liu Y; He J; Benitez R; Buckanovich RJ; Lubman DM
J Proteome Res; 2012 Sep; 11(9):4541-52. PubMed ID: 22827608
[TBL] [Abstract][Full Text] [Related]
25. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine.
Ye B; Skates S; Mok SC; Horick NK; Rosenberg HF; Vitonis A; Edwards D; Sluss P; Han WK; Berkowitz RS; Cramer DW
Clin Cancer Res; 2006 Jan; 12(2):432-41. PubMed ID: 16428483
[TBL] [Abstract][Full Text] [Related]
26. The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria.
Abogunrin F; O'Kane HF; Ruddock MW; Stevenson M; Reid CN; O'Sullivan JM; Anderson NH; O'Rourke D; Duggan B; Lamont JV; Boyd RE; Hamilton P; Nambirajan T; Williamson KE
Cancer; 2012 May; 118(10):2641-50. PubMed ID: 21918968
[TBL] [Abstract][Full Text] [Related]
27. Tissue and serum proteomic profiling for diagnostic and prognostic bladder cancer biomarkers.
Schwamborn K; Gaisa NT; Henkel C
Expert Rev Proteomics; 2010 Dec; 7(6):897-906. PubMed ID: 21142890
[TBL] [Abstract][Full Text] [Related]
28. Proteomics analysis of bladder cancer exosomes.
Welton JL; Khanna S; Giles PJ; Brennan P; Brewis IA; Staffurth J; Mason MD; Clayton A
Mol Cell Proteomics; 2010 Jun; 9(6):1324-38. PubMed ID: 20224111
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic values of urine CYFRA21-1, NMP22, UBC, and FDP for the detection of bladder cancer.
Jeong S; Park Y; Cho Y; Kim YR; Kim HS
Clin Chim Acta; 2012 Dec; 414():93-100. PubMed ID: 22944145
[TBL] [Abstract][Full Text] [Related]
30. The clinical value of CYFRA21-1 in bladder cancer patients: Egyptian experience.
el-Ahmady O; Halim AB; el-Din AG
Anticancer Res; 1999; 19(4A):2603-8. PubMed ID: 10470202
[TBL] [Abstract][Full Text] [Related]
31. [Clinical evaluation of urinary NMP22 (nuclear matrix protein 22) bladder chek in the detection of patients with bladder cancer].
Kitsukawa S; Yamamoto Y; Hosoda S; Otsuru N; Matsumoto T; Matsumoto T; Aizawa T; Noda K; Ito T
Hinyokika Kiyo; 2006 Mar; 52(3):167-72. PubMed ID: 16617867
[TBL] [Abstract][Full Text] [Related]
32. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
33. Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry metabolomics approach.
Alberice JV; Amaral AF; Armitage EG; Lorente JA; Algaba F; Carrilho E; Márquez M; García A; Malats N; Barbas C
J Chromatogr A; 2013 Nov; 1318():163-70. PubMed ID: 24139504
[TBL] [Abstract][Full Text] [Related]
34. Isotope coded protein label quantification of serum proteins--comparison with the label-free LC-MS and validation using the MRM approach.
Turtoi A; Mazzucchelli GD; De Pauw E
Talanta; 2010 Feb; 80(4):1487-95. PubMed ID: 20082806
[TBL] [Abstract][Full Text] [Related]
35. Comparison of nuclear matrix protein 22 and bladder tumor antigen in urine of patients with bladder cancer.
Abbate I; D'Introno A; Cardo G; Marano A; Addabbo L; Musci MD; Pagliarulo A; Correale M; Quaranta M
Anticancer Res; 1998; 18(5B):3803-5. PubMed ID: 9854500
[TBL] [Abstract][Full Text] [Related]
36. IMAC fractionation in combination with LC-MS reveals H2B and NIF-1 peptides as potential bladder cancer biomarkers.
Frantzi M; Zoidakis J; Papadopoulos T; Zürbig P; Katafigiotis I; Stravodimos K; Lazaris A; Giannopoulou I; Ploumidis A; Mischak H; Mullen W; Vlahou A
J Proteome Res; 2013 Sep; 12(9):3969-79. PubMed ID: 23924207
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of head-and-neck cancer biomarkers previously discovered and identified using iTRAQ-labeling and multidimensional liquid chromatography-tandem mass spectrometry.
Matta A; DeSouza LV; Shukla NK; Gupta SD; Ralhan R; Siu KW
J Proteome Res; 2008 May; 7(5):2078-87. PubMed ID: 18407684
[TBL] [Abstract][Full Text] [Related]
38. Proteomic identification of salivary biomarkers of type-2 diabetes.
Rao PV; Reddy AP; Lu X; Dasari S; Krishnaprasad A; Biggs E; Roberts CT; Nagalla SR
J Proteome Res; 2009 Jan; 8(1):239-45. PubMed ID: 19118452
[TBL] [Abstract][Full Text] [Related]
39. Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma.
Bian W; Xu Z
Int J Urol; 2007 Feb; 14(2):108-11. PubMed ID: 17302565
[TBL] [Abstract][Full Text] [Related]
40. Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma.
Passerotti CC; Srougi M; Bomfim AC; Martins JR; Leite KR; Dos Reis ST; Sampaio LO; Ortiz V; Dietrich CP; Nader HB
Urol Oncol; 2011; 29(6):710-5. PubMed ID: 19962919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
